Survey of malignant pleural mesothelioma treatment in Japan: Patterns of practice and clinical outcomes in tomotherapy facilities

Abstract We conducted a nationwide survey of tomotherapy for malignant pleural mesothelioma (MPM) in Japan. Fifty-six facilities were surveyed and data on 31 patients treated curatively between 2008 and 2017 were collected from 14 facilities. Twenty patients received hemithorax irradiation after extrapleural pneumonectomy (EPP) (first group). Five patients received irradiation without EPP (second group), while six received salvage radiotherapy for local recurrence (salvage group). Among the seven patients not undergoing EPP, five (four in the second group and one in the salvage group) were treated with lung sparing pleural irradiation (LSPI) and two with irradiation to visible tumors. Two-year overall survival (OS) rates in the first and second groups were 33% and 60%, respectively (median, 13 vs 30 months, P = 0.82). In the first and second groups, 2-year local control (LC) rates were 53 and 67%, respectively (P = 0.54) and 2-year progression-free survival (PFS) rates were 16% and 60%, respectively (P = 0.07). Distant metastases occurred in 15 patients in the first group and three in the second group. In the salvage group, the median OS was 18 months. Recurrence was observed in the irradiated volume in four patients. The contralateral lung dose was higher in LSPI than in hemithorax irradiation plans (mean, 11.0 ± 2.2 vs 6.1 ± 3.1 Gy, P = 0.002). Grade 3 or 5 lung toxicity was observed in two patients receiving EPP and hemithorax irradiation, but not in those undergoing LSPI. In conclusion, outcomes of EPP and hemithorax irradiation were not satisfactory, whereas LSPI appeared promising and encouraging.

[1]  A. Mansfield,et al.  First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial , 2021, The Lancet.

[2]  C. Simone,et al.  Disease-Related Outcomes and Toxicities of Intensity-Modulated Radiation Therapy Following Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review. , 2020, Practical radiation oncology.

[3]  Tim Lesley Kyle Sally Kurt Degu Omar Dilaram Mohsen Fa Driscoll Rushton Steenland Hutchings Straif A Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016 , 2020, Occupational and Environmental Medicine.

[4]  K. Nackaerts,et al.  Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  M. Slade,et al.  British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma , 2018, Thorax.

[6]  S. Armato,et al.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Wu,et al.  Radiotherapy for the treatment of malignant pleural mesothelioma. , 2017, The Lancet. Oncology.

[8]  E. Yorke,et al.  Improved Outcomes with Modern Lung‐Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  K. Okabe Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma. , 2017, Annals of translational medicine.

[10]  Kunihiko Kobayashi,et al.  Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion. , 2017, Lung cancer.

[11]  E. Yorke,et al.  Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Olivier Molinier,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[13]  K. Nackaerts,et al.  Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. , 2015, The Lancet. Oncology.

[14]  T. Yamanaka,et al.  Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial) , 2015, International Journal of Clinical Oncology.

[15]  A. Del Conte,et al.  Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors. , 2015, International journal of radiation oncology, biology, physics.

[16]  R. Mak,et al.  Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma. , 2015, The Journal of thoracic and cardiovascular surgery.

[17]  E. Yorke,et al.  Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma. , 2014, International journal of radiation oncology, biology, physics.

[18]  W. Richards,et al.  Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural Mesothelioma: Novel Prognostic Implications of Combined N1 and N2 Nodal Involvement Based on Experience in 529 Patients , 2014, Annals of surgery.

[19]  L. Sharples,et al.  Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial , 2014, The Lancet.

[20]  Y. Shibamoto,et al.  Helical and Static-port Tomotherapy Using the Newly-developed Dynamic Jaws Technology for Lung Cancer , 2014, Technology in cancer research & treatment.

[21]  Y. Shibamoto,et al.  Intensity-modulated radiation therapy using static ports of tomotherapy (TomoDirect): comparison with the TomoHelical mode , 2013, Radiation oncology.

[22]  J. Peto,et al.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study , 2011, The Lancet. Oncology.

[23]  B. McCaughan,et al.  A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  F. Kjaer-Kristoffersen,et al.  Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  Laurence Court,et al.  Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. , 2006, International journal of radiation oncology, biology, physics.

[26]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.